83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes.

Authors :: Martin Jimenez, M.
Gnant, M.I.
Ejlertsen, B.
Mansi, J.L.
Ruiz-Borrego, M.
Jakobsen, E.H.
Osborne, C.K.
Birhiray, R.
Zhang, B.
Wong, A.
Moy, B.
Holmes, F.A.
Source :: Annals of Oncology. 2020 Supplement 2, Vol. 31, pS43-S43. 1p. 1 Chart.
Publication Year :: 2020

Subjects :: *ADJUVANT treatment of cancer
*TREATMENT duration
*HORMONE receptor positive breast cancer
*TRASTUZUMAB
*TREATMENT effectiveness
*BREAST cancer patients

Full Text Access

Tools